Media

BONESUPPORT™ FILES FDA SUBMISSION FOR CERAMENT® V

U.S. Food and Drug Administration removes clinical hold of Oncopeptides’ pipeline drug OPD5

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Doctrin expands to France as Ramsay Santé chooses platform for outpatient psychiatry digitalization

Intervacc’s variation application approved by VMD

Tribune Therapeutics raises EUR 37 million for next-generation anti-fibrotic therapies

Vicore publishes the Annual Report for 2024

Aprea Therapeutics reports fourth quarter and full year 2024 financial results and provides a business update

Oncorena receives FDA approval to initiate studies in the US

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)